December 10, 2013
The Federal Trade Commission asked a Pennsylvania federal judge Monday to add Teva Pharmaceutical Industries Ltd. as a defendant in its antitrust suit over payments Provigil maker Cephalon Inc. made to block generic versions of its drug, citing Teva's acquisition of the company.
November 19, 2013
The Federal Trade Commission told a Pennsylvania federal court Monday that the launch of generic versions of Cephalon Inc.'s Provigil did not moot its pay-for-delay suit against the drugmaker, because it can still pursue the billions of dollars Cephalon made while the deals were in place.
September 11, 2013
A Pennsylvania federal judge ruled Wednesday that attorney-client privilege prevented the release of most of the documents sought by the Federal Trade Commission in an antitrust suit accusing Cephalon Inc. of improperly delaying generic versions of its narcolepsy drug.
August 08, 2013
A Pennsylvania federal judge agreed Thursday to an in camera review to determine whether attorney-client privilege prevented the release of more than 50 documents sought by the Federal Trade Commission in an antitrust suit accusing Cephalon Inc. of improperly delaying generic versions of its narcolepsy drug.
August 30, 2012
A judge overseeing a long-running pay-for-delay dispute brought by the Federal Trade Commission and others against Cephalon Inc. stayed the cases Wednesday over the objections of the plaintiffs until the U.S. Supreme Court decides whether to hear another case on the underlying antitrust issue.
September 01, 2009
Cephalon Inc. has asked a federal judge to dismiss the Federal Trade Commission's ongoing antitrust suit alleging that the drugmaker illegally paid off generics competitors in a reverse payment agreement over the patent for narcolepsy drug Provigil.
July 28, 2009
A judge on Tuesday asked for all motions to be refiled in the Federal Trade Commission's ongoing antitrust suit alleging Cephalon Inc. paid off generic competitors in the market for its narcolepsy drug Provigil.